Autifony Therapeutics
Generated by Meeveem AI
"Translating pioneering ion channel science into new treatments for rare CNS disorders"
Stevenage
•11 - 50 Employees
•Biotechnology
About Autifony Therapeutics
Autifony Therapeutics develops small molecule drugs targeting ion channels to treat rare genetic CNS disorders. Their lead programmes include AUT00206 for Fragile X syndrome with FDA Orphan Drug Designation, and AUT00201 for rare epilepsy. Their platform combines ion channel biology expertise with drug discovery to create precision medicines for conditions with limited treatment options. Patients with Fragile X syndrome, myoclonic epilepsy, and schizophrenia benefit from this approach, which targets biological mechanisms driving neural dysfunction. By focusing on genetically defined conditions with clear unmet need, Autifony is building a pipeline that could transform how these devastating neurological conditions are managed.
25
Team Members
2011
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A future where rare genetic CNS disorders are no longer untreatable, with precision medicines targeting the ion channel dysfunctions at their core, restoring normal brain function and transforming patients' lives.
Our Mission
Autifony's mission is to change the treatment paradigm for patients with rare CNS disorders by translating pioneering ion channel science into innovative medicines that address the root causes of disease.